About Dr. Isabelle Brock Eds Expert

PERSONAL STATEMENT

Dr. Isabelle Brock has dedicated her professional career to the research and understanding of connective tissue issues, aiming to improve the quality of life and provide access to care for her clients.

As the President and CEO of QoLify and the NovaCombian Research Institute, Dr. Brock is a visiting scientist at the department of medical and molecular genetics at the IU School of Medicine where she is establishing the center of excellence for Ehlers Danlos Syndromes clinic and performing research in to EDS and its comorbidities.

As advisor for the Centers and Networks of Excellence Program for The Ehlers-Danlos Society, she has dedicated herself to establishing networks around the globe to give patients with EDS better access to care. Dr. Brock has co-founded Clinical Paradigms a clinic for people with complex connective tissue diseases.

Dr. Brock is the chair of the Pain management group and a member of the Allergy, Immunology Working Group of the International Consortium on EDS and its Comorbidities.

She is a member in the AHEAD Coalition (treating pediatric pain) and the ‘Breaking Down Barriers’ Initiative of the EDS Society.

Dr. Brock currently serves as Vice-President for the Research & Study Group for EDS (GERSED) in France and is a member of the Belgian GERSED. In addition to serving as the Chief Scientific Officer at the EDS Initiative – Deutschland, where she spearheads the committee for producing the German guidelines on EDS, she is a member of the scientific committee of the Foundation for Research & Advocacy in Muscle Pain Education (FRAME) and formerly held positions as Lead Scientist at the Hospital Hotel Dieu de Paris, and at Ellasanté, Paris.

Further education includes certification in diagnosis and treatment for Ehlers-Danlos Syndromes (EDS) from Paris Est Créteil University and certification in Ayurvedic Medicine for Medical Professionals from the Institute of Ayurveda & Alternative Medicine, University of Ruhuna, Sri Lanka. She is currently earning a degree in Acupuncture and Traditional Chinese Medicine in the Master of Science of Oriental Medicine Program at Pacific College. Further accomplishments include her having co-created and taught tele-courses on EDS for medical professionals and spearheaded the establishment of three clinics dedicated to helping patients with EDS and its comorbidities. Dr. Brock is the co-author of “Transforming Ehlers-Danlos Syndrome: A Global Vision of the Disease – The Epigenetic Revolution – Emergencies”.

She has produced two medical devices (patent pending) for the treatment of proprioception as well as cortisol deficiencies.

RESEARCH AND PROFESSIONAL EXPERIENCE

Department of Connective Tissue, NovaCombian Research Institute, Head of Department

New York, NY, USA, current since 2021

NovaCombian clinic, Program Director, clinic for complex connective tissue disease patients, Barberyn Reef Hospital, Beruwala, Sri Lanka, current since 2022

The Ehlers-Danlos Society Centers and Networks of Excellence Program, Program Advisor, Indianapolis, IN, USA, current since 2022

Clinical Paradigms, Chief Scientific Officer, clinic for the complex disease patient in the trifecta of Ehlers Danlos Syndrome, Mast Cell Activation Disease and Dysautonomia, New York, NY, USA, current since 2021

Department of Medical and Molecular Genetics, Indiana University School of Medicine, Visiting Scientist, Indianapolis, IN, USA, current since 2020

Establishing a Center of Excellence for patients with Ehlers-Danlos-Syndrome within the genetics department, researching EDS and its comorbidities.

Quality of Life Improvements For You (QOLIFY), CEO and Sr Clinical Researcher, New York, NY, USA, current since 2019

Uniquely combines a research institute and a platform to provide comprehensive services and products to the EDS (Ehlers-Danlos syndrome) community. Qolify opened a clinic for patients with connective tissue diseases incorporating different medical and paramedical specialties in New York City.

GERSED is an association of physicians researching, studying, diagnosing and treating EDS.

International Clinical Project Manager/Lead Researcher for defining diagnostic criteria and treatment options for EDS. Design and implement Phase, I, II, and III projects. Responsible for drafting: study protocols, case report forms and guidelines for clinical practice. Train physicians in treatment and diagnosis of EDS. Organized, presented and facilitated, “The Annual EDS International French Symposium” (2015-2019) and the “Annual National French Symposium” (2018, 2019).

Ellasanté, Chief of Research, 2016 – 2017, Paris, France

Ellasanté is a comprehensive specialty clinic for the treatment of EDS. Chief of research, physicians’ assistant to 10 MDs in the Ehlers-Danlos clinic. Screened all incoming patients, assisted in developing treatment plans based upon surveying the entirety of the current research in the field. Responsible for coordinating and publishing research.

Hospital Hôtel Dieu de Paris, Lead Scientist, 2014 – 2016, Paris, France

Lead Scientist/physicians’ assistant to 6 MDs in the EDS clinic. Researched and updated the diagnostic criteria and screening tools for EDS. Partnered with Orthopédie Vlamynck (the primary corporation for the treatment of dys-proprioception caused by EDS). Measured the clinical results of compressive medical gear/garments on the mitigation of symptoms and quality of life for EDS patients.  2015 – 2019

RESEARCH AND PROFESSIONAL EXPERIENCE (continued).

AFFILIATIONS

Ehlers-Danlos Society, member of the International Consortium on EDS:

Chair of the Pain Management Group, chair of the Literature Review Group, member of the Allergy and Immunology group.

Program Director – Global Centers and Networks of Excellence

Keynote Panelist 2016-current

US: Foundation for Research and Advocacy in Muscle pain Education (FRAME). Member of scientific committee.

France: GERSED (Groupe d’Etude et de Recherche Syndrome Ehlers Danlos) President, Keynote Speaker 2016-current

Germany: EDS Initiative Deutschland, Chief Scientific Officer of its scientific committee. Keynote Speaker 2018-current.

GRANTS

a $600,000 award from the Bruhn-Morris Family Foundation with a 1:1 matching award from IU Health Foundation, for a total of $1.2 Million, to establish a global network of Centers of Excellence for Ehlers-Danlos syndrome and Hypermobility Spectrum Disorders over the next four years

LANGUAGES

French/German – bilingual proficiency; English, Italian, Swedish, Norwegian – Full professional proficiency

PUBLICATIONS

1.      Pizano J., Zingman A., Brock I., Maitland A., Schubart J., Francomano C., Nutritional Markers of Histamine Intolerance in Ehlers-Danlos Syndromes. Genetics in Medicine Open, Volume 1, Issue 1, Supplement 100197, 2023

2.      Brock I., Maitland A., Mast Cells and COVID-19: A Case Report Implicating a Role of Mast Cell Activation in the Prevention and Treatment of COVID-19. J Vaccines Vaccin. 2021. S12:00 DOI: 10.35248/2157-7560.21.s12.005

3.      Brock I., Prendergast W., Maitland A., Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder. Am J Med Genet C Semin Med Genet. 2021. doi:10.1002/ajmg.c.31940

4.      Brock I., Eng N., Maitland A., Adult-onset mast cell activation syndrome following scombroid poisoning: a case report and review of the literature. J Med Case Rep. 2021. doi:10.1186/s13256-021-03190-w

5.      Hamonet C., Brock I., Hamonet-Dewez M., Brissot R., Local Multiple Injections of Lidocaine as a Very Efficient Treatment of Intractable Pains in Ehlers-Danlos Disease. The Dysproprioception Hypothesis. EC Anaesthesia. 2019;5(9):290-296

6.      Hamonet, C., Gompel, A., Baeza-Velasco, Ducret, L., Metlaine, A., Ehlers-Danlos Syndrome ( EDS )-Contribution to Clinical Diagnosis-A Prospective Study of 853 Patients. EC Neurology 2018;10.6

7.      Chopra P., Tinkle B., Hamonet C., Brock I., Gompel A., Bulbena A., Francomano C., Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):212-219. doi:10.1002/ajmg.c.31554

8.      Hamonet C., Brock I., Pommeret S., et al. Syndrome d’Ehlers-Danlos (SED) Type III (Hypermobile): Validation d’une Échelle Clinique Somatosensorielle (ECSS-62), à Propos de 626 Cas.; 2016. https://doi.org/10.1016/S0001-4079(19)30525-4

9.      Hamonet C., Ducret L., Marié-Tanay C., Brock I., Dystonia in the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome, hypermobility type). SOJ Neurol, 3(1), 1-3. 2016. DOI: 10.15226/2374-6858/3/1/00123

10.  Hamonet C, Amoretti R, Brock I, Fredy D, Baeza-Velasco C, Nourissat G. Hypermobilité, syndrome d’Ehlers-Danlos (SED) et performances sportives. Journal de Traumatologie du Sport. 2016;33(2):80-87. doi:10.1016/j.jts.2016.03.001

11.  C. Hamonet, M. Vienne, C. Leroux, M.P. Letinaud, J. Paumier, B. Dehecq, A. Metlaine, I. Brock, F.M. Bird, Manifestations respiratoires dans le syndrome d’Ehlers-Danlos (SED). Nouveaux apports thérapeutiques, Journal de Réadaptation Médicale : Pratique et Formation en Médecine Physique et de Réadaptation, Volume 36, Issue 1, 2016, Pages 56-61, https://doi.org/10.1016/j.jrm.2015.11.002

12.  Hamonet C, Brock I. Joint mobility and Ehlers-Danlos syndrome, (EDS) new data based on 232 cases. J Arthritis. 2015;04(02). doi:10.4172/2167-7921.1000148

13.  Hamonet C, Gompel A, Mazaltarine G, Brock I, Baeza-Velasco C, et al. Ehlers-Danlos Syndrome or Disease? J Syndromes. 2015;2(1): 5 DOI: 10.13188/2380-6036.1000005

14.  C. Hamonet, I. Brock, Un droit spécifique du handicap ou bien : les droits de tous pour les personnes en situation de handicap?, Journal de Réadaptation Médicale : Pratique et Formation en Médecine Physique et de Réadaptation, Volume 35, Issue 2, 2015, Pages 51-53, https://doi.org/10.1016/j.jrm.2015.03.003

BOOK

Stéphane DAENS, Isabelle DUBOIS BROCK
Transforming Ehlers-Danlos Syndrome: A Global Vision of the Disease – The Epigenetic Revolution – Emergencies January 13, 2022
ISBN: 979-8775736606